<DOC>
	<DOCNO>NCT01822314</DOCNO>
	<brief_summary>The purpose study assess efficacy neoadjuvant weekly nab-paclitaxel follow Adriamycin , Cyclophosphamide ( AC ) Epirubicin , Cyclophosphamide ( EC ) Fluorouracil , Epirubicin , Cyclophosphamide ( FEC ) compare neoadjuvant weekly solvent-based paclitaxel follow AC EC FEC term rate pathological complete remission surgery .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With Nab-paclitaxel Women With HER2-negative High-risk Breast Cancer</brief_title>
	<detailed_description>In study , eligible consent patient randomize receive either 4 cycle weekly abraxane ( nab-paclitaxel ) follow 4 cycle anthracycline-containing regimen 4 cycle weekly paclitaxel follow 4 cycle anthracycline-containing regimen.The anthracycline regimen ( AC , EC FEC ) choose investigator participate site . Before randomization patient stratify accord Disease stage [ operable ( tumor stage : T2N0-1 ; T3N0 ) locally advanced ( T3N1 ; T4 , N2-3 ) ] Tumor subtype [ luminal B intermediate ( HER2 negative , ER PGR positive , Ki67 14 % 20 % ) v luminal B high ( HER2 negative , ER PGR positive , Ki67 &gt; 20 % ) v triple negative tumor ( HER2 negative , ER negative PgR negative , Ki67 value ) ] . Tumor subtype confirm two select referral laboratory . Neoadjuvant chemotherapy follow definite surgery irradiation per international local guideline . During neoadjuvant chemotherapy patient assess safety efficacy detail protocol . After definite surgery patient follow approximately 10 year accord local procedure</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female patient age 18 year old Histologically confirm invasive unilateral breast cancer HER2negative disease Known hormone receptor status ( estrogen receptor [ ER ] , progesterone receptor [ PgR ] ) , tumor grade , institutional standard permit , know Ki67 value Available paraffinembedded tumor block take diagnostic biopsy central confirmation HER2 eligibility , hormone receptor status , Ki67 value biomarker evaluation mandatory One follow clinical stage : T2 , T3 , T4 disease , triple negative ( HER2 , ER , PgR ) T2 , T3 , T4 disease , ER PgR positive moderately differentiate poorly differentiate tumor grade ( G IIIII ) ECOG performance status 0 1 Written inform consent participate trial ( approved Institutional Review Board [ IRB ] / Independent Ethics Committee [ IEC ] ) obtain prior study specific screen procedure Willing able comply protocol Synchronous contralateral breast cancer presence metastatic disease ( M1 ) . Exception : contralateral insitu ductal cancer Surgical axillary staging procedure prior study entry . Exceptions : 1 ) Fine needle aspiration ( FNA ) axillary node permit patient , 2 ) although recommend , preneoadjuvant therapy sentinel lymph node biopsy patient clinically negative axillary node permit Pregnant lactate woman . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception , example abstinence , intrauterine device , double barrier method contraception Treatment include radiation therapy , chemotherapy , biotherapy , and/or hormonal therapy currently diagnose breast cancer prior study entry Previous investigational treatment condition within 4 week randomization date Patients therapy strong CYP3A4 inhibitor therapy Warfarin ( Coumadin ) Previous concomitant malignancy type could affect compliance protocol interpretation result . Patients curatively treat basal cell carcinoma skin situ cervix cancer generally eligible . Preexisting motor sensory neuropathy grade &gt; 1 reason Patients history hypersensitivity due drug contain polyoxyethylene castor oil ( Cremophor EL ) ( e.g. , ciclosporin ) , harden castor oil ( e.g. , vitamin preparation injection , etc . ) Other serious illness medical condition include : history document congestive cardiac failure ; angina pectoris require antianginal medication ; evidence transmural infarction ECG ; poorly control hypertension ( e.g . systolic &gt; 180 mm Hg diastolic &gt; 100 mm Hg ; however , patient hypertension well control medication eligible ) ; clinically significant valvular heart disease ; highrisk uncontrolled arrhythmias Patients history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant precluding inform consent adversely affect compliance study drug Serious uncontrolled infection ( bacterial viral ) poorly control diabetes mellitus Hematology biochemistry test within normla limit Baseline leave ventricular ejection fraction ( LVEF ) &lt; 50 % echocardiography multigated scintigraphic scan ( MUGA )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
	<keyword>unilateral</keyword>
	<keyword>non metastatic</keyword>
	<keyword>HER2 negative</keyword>
</DOC>